Clinical trials: Spinal
Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis…
- Trial name
- NCT07166315
- Testing
- observational study
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Adelphi Real World
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Spinal Muscular Atrophy, Spine Deformity
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).
- Conditions
- Spinal Muscular Atrophy, Spine Deformity, Scoliosis
- Trial name
- PIERRE (NCT05866419)
- Testing
- ThecaFlex DRx System
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 90 people
- Sponsor
- Alcyone Therapeutics, Inc
Degenerative Disc Disease
Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease
The objective of this study is to assess the safety and tolerability of YH14618 during 24 weeks of follow-up period after single administration in patients with degenerative disc disease.
- Trial name
- NCT01526330
- Testing
- YH14618
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yuhan Corporation
Low Back Pain
Safety and Efficacy Assessment of Using the zLOCK Facet Stabilization System
The zLOCK Facet Stabilization System is a fixation device intended to provide posterior stability in the lumbar spine fusion procedure.
- Trial name
- NCT05266521
- Testing
- zLOCK Facet Stabilization System
- Where
- 2 sites in Germany, Italy
- Volunteers
- 80 people
- Sponsor
- ZygoFix
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Ankylosing Spondylitis (AS)
Phase Ia Study of MST-931 in Healthy Adult Subjects
A Phase 1a, randomized, double-blind study of MST-931 in healthy participants. The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single…
- Trial name
- NCT07903493
- Testing
- MST-931
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Trial name
- PROMPT (NCT05155098)
- Testing
- secukinumab
- Where
- 10 sites in Thailand
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
This is an open-label, multi-center study designed to extend the evaluation of the safety, tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
- Trial name
- CL211 (NCT00931944)
- Testing
- KNS-760704
- Where
- 19 sites in United States
- Volunteers
- 74 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis (ALS)
A First in Human Study of ORT247 in Healthy Volunteers
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of…
- Trial name
- NCT06769620
- Testing
- ORT247
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Orthogonal Neuroscience Inc.
Spinal Cord Injury
Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD
SATURN investigates the promising role of NeuroAiD in patients with spinal cord injury and will provide important information on the feasibility of conducting larger controlled trials.
- Trial name
- SATURN (NCT02537899)
- Testing
- NeuroAiD
- Where
- Malaysia
- Volunteers
- 30 people
- Sponsor
- Moleac Pte Ltd.
Amyotrophic Lateral Sclerosis
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label…
- Trial name
- COMBAT-ALS (NCT04057898)
- Testing
- MN-166
- Where
- 16 sites in United States, Canada
- Volunteers
- 234 people
- Sponsor
- MediciNova
Diabetic Peripheral Neuropathic Pain (DPN)
Medtronic Inceptiv™ Closed-Loop DTM Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy
This study is conducted to evaluate a new way of using spinal cord stimulation (SCS) in people with painful diabetic peripheral neuropathy (DPN).
- Trial name
- MED DPN (NCT07209514)
- Testing
- Implantable SCS with Closed Loop mechanism
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TriCity Research Center
Acute Spinal Cord Injury
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in…
- Trial name
- NCT04054414
- Testing
- Normal Saline along with standard treatment, PMZ-1620 along with standard treatment
- Where
- 5 sites in India
- Volunteers
- 40 people
- Sponsor
- Pharmazz, Inc.
Acute Spinal Cord Injury
AC105 in Patients With Acute Traumatic Spinal Cord Injury
The principal aim of this study was to establish the feasibility of rapid administration, safety, and tolerability of AC105 in patients with acute spinal cord injury.
- Trial name
- AC105 (NCT01750684)
- Testing
- AC105
- Volunteers
- 15 people
- Sponsor
- Acorda Therapeutics
Amyotrophic Lateral Sclerosis
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GALS (NCT01854294)
- Testing
- GM604
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Amyotrophic Lateral Sclerosis
Safety Extension Study of TRO19622 in ALS
The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the preceding clinical trial (TRO19622 CL E Q…
- Trial name
- NCT01285583
- Testing
- TRO19622
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 271 people
- Sponsor
- Hoffmann-La Roche
Spinal Muscular Atrophy (SMA)
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
The goal of this multicenter, open-label, non-comparative, cohort study is to investigate the safety, immunogenicity, and efficacy of ANB-004 in children with spinal muscular atrophy.
- Trial name
- BLUEBELL (NCT05747261)
- Testing
- ANB-004, dose 1, ANB-004, dose 2, ANB-004, dose 3
- Where
- 7 sites in Belarus, Russia
- Volunteers
- 40 people
- Sponsor
- Biocad
Degenerative Disc Disease
Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® device as compared to the LT-CAGE® device with autogenous bone in patients with symptomatic degenerative disc disease using an open…
- Trial name
- NCT01491386
- Testing
- rhBMP-2/ACS/LT-CAGE® Device, Autogenous Bone/LT-CAGE® Device
- Volunteers
- 279 people
- Sponsor
- Medtronic Spinal and Biologics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.